# Seres Therapeutics (MCRB) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/MCRB
## Company Profile
- Ticker: MCRB
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 2.63 USD
- Market cap: 70983236.22 USD
- Last updated: 2026-10-08
## Business Overview
### Live Biotherapeutic Platform
Seres Therapeutics develops live biotherapeutics that alter the gut microbiome to treat inflammatory and immune-mediated disease. The company previously led development of VOWST, the first orally administered FDA-approved microbiome therapeutic, before divesting it to Nestlé Health Science.
### SER-155
SER-155 is a defined bacterial consortium intended to reduce serious infections and modulate immune complications in vulnerable patients. It is Phase 2 ready for prevention of bloodstream infections after allogeneic hematopoietic stem-cell transplantation and has received Breakthrough Therapy and Fast Track designations.
### Checkpoint-Inhibitor Enterocolitis
An investigator-sponsored trial at Memorial Sloan Kettering is evaluating SER-155 in immune checkpoint inhibitor-related enterocolitis. This program tests whether the candidate can address a severe inflammatory toxicity associated with cancer immunotherapy and potentially open adjacent immune-disease indications.
### SER-603
SER-603 is a preclinical live biotherapeutic program for inflammatory bowel disease. Seres is conducting IND-enabling work and seeking collaborators to support development as a monotherapy or combination treatment.
## Why The Stock Is Moving

As of Oct 8, 2026, MCRB closed down 3.31% at $2.63. No new same-company headline was identified in the current news window.

## Future Catalysts

- Clinical data from the completed investigator-sponsored SER-155 enterocolitis study expected in the coming weeks.

## Drug Assets

- SER-155

## Recent News
- 2026-09-08 22:00 EST — [Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/MCRB/seres-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ce2df6c9) — Source: Seres Therapeutics
- 2026-09-01 11:00 EST — [Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference](https://biopharmsignal.com/news/MCRB/seres-therapeutics-to-participate-in-h-c-wainwright-28th-annual-global-investmen-41e66f35) — Source: Seres Therapeutics
- 2026-08-05 11:00 EST — [Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs](https://biopharmsignal.com/news/MCRB/seres-therapeutics-reports-second-quarter-2026-financial-results-and-provides-bu-592fe156) — Source: Seres Therapeutics
- 2026-07-08 11:00 EST — [Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment](https://biopharmsignal.com/news/MCRB/seres-therapeutics-announces-early-clinical-data-showing-potential-for-ser-155-i-55053722) — Source: Seres Therapeutics
- 2026-06-25 11:00 EST — [Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis](https://biopharmsignal.com/news/MCRB/seres-therapeutics-to-host-webcast-on-july-8-2026-to-discuss-results-of-investig-6fc7afb2) — Source: Seres Therapeutics